Tau-based vaccines could transform early Alzheimer's treatment, says analyst

While current treatments for Alzheimer’s disease (AD) are only able to ease symptoms temporarily, tau-based vaccines may offer a new and more effective way to treat AD in the early course of the disease, says an analyst.

According to Kyle Nicholson, an analyst at research and consulting firm GlobalData's covering neurology, tau-based therapies for AD have traditionally been overlooked in favor of passive beta amyloid immunotherapies, such as Eli Lilly’s (NYSE: LLY) solanezumab and Roche’s (ROG: SIX) gantenerumab and crenezumab.

However, this interest appears to be receding after notable setbacks in recent years, and tau-based immunotherapies now have the potential to capture larger patient shares than these products.